文献速递关节外科

工业资助与非资助的全关节置换术后血栓预防研究在报告结局上的差异

Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
PubMed 文献 · J Arthroplasty · 2018-06-28

该研究通过检索Ovid、PubMed和Embase数据库,纳入2000至2016年发表的57项评估全髋或全膝关节置换术后静脉血栓栓塞预防的研究,其中29项为工业资助、28项为非资助。工业资助研究报告的肺栓塞、大出血和90天死亡率均少于非资助研究,但文献缺乏详细人口学数据,无法阐明结局差异的原因。

要点

  • 工业资助研究29项 vs 非资助研究28项,患者年龄、体重指数或翻修排除标准无显著差异。
  • 工业资助研究报告的肺栓塞和大出血事件少于非资助研究。
  • 工业资助研究报告的90天死亡率显著低于非资助研究。

核心结论

  • 工业资助研究与非资助研究相比,报告的肺栓塞、大出血和死亡率均更少。
  • 文献中缺失详细的人口学数据,作者无法证明工业资助与非资助研究之间报告结局不同的原因。
  • 作者认为进一步研究应着眼于理解为何资助研究在全关节置换术后静脉血栓栓塞分析中报告更少的不良结局。

研究设计与样本

  • 电子检索Ovid、PubMed和Embase数据库。
  • 纳入标准为:2000年至2016年间以英文发表;纳入接受全髋关节置换术或全膝关节置换术的患者;评估术后静脉血栓栓塞的预防和控制,且至少使用以下一种血栓预防药物:阿司匹林、依诺肝素、达肝素、达比加群、阿哌沙班、利伐沙班、达比加群、希美加群、磺达肝癸钠或华法林。
  • 共纳入57项研究,其中29项为工业资助,28项为非资助。
  • 数据通过混合效应逻辑回归进行分析。

主要发现

  • 工业资助研究与非资助研究在患者年龄、体重指数或翻修排除标准方面无显著差异。
  • 工业资助研究报告的肺栓塞少于非资助研究。
  • 工业资助研究报告的大出血事件少于非资助研究。
  • 工业资助研究报告的90天死亡率显著低于非资助研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 文献中缺失详细的人口学数据。
  • 作者无法证明工业资助研究与非资助研究之间报告结局不同的原因。
  • 作者认为进一步研究应着眼于理解为何资助研究在全关节置换术后静脉血栓栓塞分析中报告更少的不良结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are numerous studies discussing thromboprophylaxis after total joint arthroplasty (TJA), with varying conclusions. Patient inclusion criteria may be different for each study, which may lead to selection bias and misrepresentation of data. This study aimed to investigate if industry funding impacted patient demographics and overall reported outcomes of studies analyzing venous thromboembolism (VTE) prevention after TJA. METHODS: Electronic searches were completed using Ovid, PubMed, and Embase databases. Studies were included if (1) they are published in the English language between 2000 and 2016; (2) they included patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA); and (3) they evaluated prevention and control of postoperative VTE with at least one of the following thromboprophylactic agents: aspirin, enoxaparin, dalteparin, dabigatran, apixaban, rivaroxaban, dabigatran, ximelagatran, fondaparinux, or coumadin. Data were extracted and analyzed via mixed-effect logistic regression. RESULTS: Fifty-seven studies were included; 29 were industry funded, and 28, nonfunded. There were no significant differences between patient's age, body mass index, or revision exclusions between funded and nonfunded studies. Funded studies reported less pulmonary embolisms, fewer events of major bleeding, and significantly less 90-day mortality compared with nonfunded studies. CONCLUSION: Industry-funded studies reported less pulmonary embolisms, major bleeding, and mortality compared with nonfunded studies. Detailed demographic data were missing from the literature, and we were unable to demonstrate the cause of different reported outcomes between industry-funded and nonfunded studies. Further investigations should be aimed toward understanding how funded studies report less adverse outcomes in analyzing VTE after TJA.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Groff H, Azboy I, Parvizi J, et al. Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. J Arthroplasty. 2018. PMID: 30017220. doi:10.1016/j.arth.2018.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。